A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer
The purpose of this study is to examine if Nivolumab alone or in combination with Ipilimumab will demonstrate a meaningful objective response rate in patients with recurrent and metastatic colon cancer who also have a specific biomarker in their tumors.
• Histologically confirmed colorectal cancer
• Measurable disease by CT or MRI
• Adequate organ function as defined by study-specific laboratory tests
Todd Crocenzi, M.D.
Bristol Myers Squibb (BMS)
- Oncology and Hematology Care Eastside